Toulouse University Hospital

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.chu-toulouse.fr

Clinical Trials

Mesenchymal Stem Cells and Myocardial Ischemia

Phase 1

Completed

Conditions: Left Ventricular Dysfunction
Chronic Myocardial Ischemia

Interventions: Genetic: Mesenchymal stem cells

First Posted Date: 2010-02-26

Last Posted Date: 2014-09-19

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 10

Registration Number: NCT01076920

Locations: 🇫🇷
University Hospital (Rangueil), Toulouse, France

Transcranial Magnetic Stimulation for Borderline Personality Disorder

Not Applicable

Completed

Conditions: Borderline Personality Disorder

Interventions: Procedure: repetitive Transcranial Stimulation Magnetic (rTMS)
Procedure: sham rTMS

First Posted Date: 2010-02-26

Last Posted Date: 2017-05-11

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 13

Registration Number: NCT01076933

Locations: 🇫🇷
Lionel Cailhol, Toulouse, University Hospital Toulouse, France

Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study

Not Applicable

Completed

Conditions: Multisystemic Atrophy

Interventions: Radiation: H215O PET
Drug: Levodopa

First Posted Date: 2010-01-08

Last Posted Date: 2010-02-26

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 38

Registration Number: NCT01044992

Locations: 🇫🇷
University Hospital, Toulouse, France

Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo

Phase 2

Completed

Conditions: Prader Willi Syndrome

Interventions: Drug: Syntocinon®/- Spray
Drug: Physiological serum (Sodium chloride)

First Posted Date: 2009-12-24

Last Posted Date: 2017-05-12

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 24

Registration Number: NCT01038570

Locations: 🇫🇷
Hôpital marin d'Hendaye, Hendaye, Pyrénées-Atlantiques, France

Anticoagulant Clinics and Vitamin K Antagonists

Phase 4

Completed

Conditions: Blood Coagulation Disorders

Interventions: Drug: Anticoagulant (warfarin, acenocoumarol, fluindione)

First Posted Date: 2009-08-26

Last Posted Date: 2009-08-26

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 1006

Registration Number: NCT00966290

Locations: 🇫🇷
Dupuytren University Hospital, Limoges, France
🇫🇷
University Hospital, Strasbourg, France
🇫🇷
Bellevue University Hospital, Saint-Etienne, France

and more 2 locations

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders

Completed

Conditions: Hemolytic Auto-immune Anaemia
Auto-immune Thrombocytopenic Purpura
Pemphigus
Cold Agglutinin Disease
Cryoglobulinemia

Interventions: Drug: Rituximab (MABTHERA® or RITUXAN®).

First Posted Date: 2009-08-18

Last Posted Date: 2012-10-23

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 35

Registration Number: NCT00960713

Locations: 🇫🇷
Service de médecine interne, hôpital Purpan, place du Dr Baylac, Toulouse, France

Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain

Phase 2

Completed

Conditions: Neuropathic Pain

Interventions: Drug: Ketamine

First Posted Date: 2009-08-18

Last Posted Date: 2014-12-02

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 22

Registration Number: NCT00961194

Locations: 🇫🇷
Service de Neurochirurgie, Toulouse, France

Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Detemir insulin, Aspart insulin, Metformin

First Posted Date: 2009-07-20

Last Posted Date: 2013-12-11

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 52

Registration Number: NCT00942318

Locations: 🇫🇷
University Hospital Toulouse, Toulouse, France

Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment

Phase 4

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2009-07-20

Last Posted Date: 2011-03-30

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 300

Registration Number: NCT00942214

Locations: 🇫🇷
service de neurologie, hôpital Purpan, Toulouse, France

Dopaminergic Loss and Pain in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease
Pain

Interventions: Drug: ioflupane 123I (DATSCAN®)

First Posted Date: 2009-07-17

Last Posted Date: 2020-07-29

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 20

Registration Number: NCT00940914

Locations: 🇫🇷
University Hospital Toulouse, Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy